CLINICAL RECORD / SURPASS · SURMOUNT · BEYOND
Tirzepatide research: receptor pharmacology, SURPASS/SURMOUNT outcomes, and the expanding indication record.
Comprehensive literature digest across mechanism, efficacy, safety, and emerging indications — each finding status-tagged and cited.
The short version
Tirzepatide is the first approved drug to activate two incretin receptors — the GIP receptor and the GLP-1 receptor — with a single peptide molecule. 'Incretin' refers to gut-derived hormones released after eating that help the body control blood sugar. By activating both, tirzepatide improves blood sugar control more than drugs targeting only GLP-1, and produces larger weight reductions. The highest quality evidence comes from the SURPASS phase 3 programme (type 2 diabetes) and the SURMOUNT programme (obesity). In SURMOUNT-1 (2539 adults, 72 weeks), the 15 mg dose reduced body weight by an average of nearly 21% — the largest weight reduction recorded for any approved drug in the trial to that point. A head-to-head RCT in people with obesity (SURMOUNT-5) confirmed tirzepatide outperforms semaglutide for weight loss. Tirzepatide has since been approved for obstructive sleep apnea and is under study for liver disease and heart failure.
Discovery and receptor pharmacology
The 2018 discovery paper for LY3298176 (tirzepatide) demonstrated dual GIP and GLP-1 receptor agonism in vitro and showed that chronic administration in mice reduced body weight and food intake significantly more than a selective GLP-1 receptor agonist alone [1]. Phase 1 work in 142 subjects confirmed pharmacokinetics supporting once-weekly subcutaneous dosing, with reduced fasting glucose and body weight versus placebo [1].
In vitro receptor-occupancy and signalling assays (Willard et al., 2020) characterised tirzepatide as an imbalanced dual agonist: it engages the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R) and shows biased GLP-1R signalling favouring cyclic AMP (cAMP) generation over beta-arrestin recruitment — with weaker GLP-1R internalisation than native GLP-1. Beta-arrestin1 limits the insulin response to native GLP-1 but not to GIP or tirzepatide, explaining part of the potency advantage [2].
Cryo-EM structural studies revealed the near-atomic molecular basis for the dual engagement: key receptor-ligand interactions at both GIPR and GLP-1R binding interfaces, confirming both common and unique features of dual versus single agonism [8]. GIP and GLP-1 receptors are expressed across liver, muscle, adipose tissue, central nervous system, heart, and kidney, enabling tirzepatide's dual engagement to produce cardiometabolic benefits through multiple partly distinct tissue-level pathways [9].
Tirzepatide vs semaglutide
In SURPASS-2 (open-label 40-week phase 3 RCT, n=1879 T2DM adults), once-weekly tirzepatide at 5, 10, and 15 mg reduced HbA1c by 2.01, 2.24, and 2.30 percentage points versus 1.86 percentage points with semaglutide 1 mg — superior at all doses. Body-weight treatment differences: -1.9, -3.6, and -5.5 kg [3]. In SURMOUNT-5 (open-label 72-week phase 3b RCT, n=751 adults with obesity but not T2DM), tirzepatide at the maximum tolerated dose produced a mean weight change of -20.2% versus -13.7% with semaglutide at maximum tolerated dose (p<0.001), with higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss [5]. An indirect comparison versus oral semaglutide 50 mg (adjusted for sex, ethnicity, and baseline) found weight differences of -4.48% (10 mg) and -5.59% (15 mg) in favour of tirzepatide [13].
Glycaemic efficacy — the SURPASS programme
SURPASS-1: as monotherapy in adults with T2DM inadequately controlled by diet and exercise, once-weekly tirzepatide produced dose-dependent HbA1c and weight reductions versus placebo [16].
SURPASS-2: superior to semaglutide 1 mg on HbA1c and weight over 40 weeks in 1879 adults with T2DM [3] (detail above).
SURPASS-3: tirzepatide superior to insulin degludec on HbA1c and weight, added to metformin (with or without an SGLT2 inhibitor) in T2DM over 52 weeks [17].
SURPASS-5: tirzepatide added to insulin glargine significantly improved glycaemic control and reduced body weight versus placebo in T2DM inadequately controlled on insulin glargine [18]. A JAMA trial confirmed this benefit in a titrated insulin glargine setting [19].
A meta-analysis of 6 RCTs (6,579 participants) across the SURPASS programme confirmed dose-response effects: HbA1c reduction WMD -1.07 percentage points (95% CI -1.44 to -0.56), fasting serum glucose WMD -21.50 mg/dL, and body weight WMD -7.99 kg versus controls, without increased hypoglycaemia risk as monotherapy or add-on [12].
A mechanistic substudy (Thomas et al., 2020) reported that tirzepatide improved markers of beta-cell function (the insulin-producing cells in the pancreas) and insulin sensitivity in people with T2DM [38].
A GIPR-blocking human islet study (El et al., 2023) confirmed that GIPR engagement contributes meaningfully to tirzepatide's insulin secretion in human tissue — and that this contribution differs from mouse islets, where GLP-1R drives more of the effect [11].
A pooled SURPASS analysis in older adults (65+ years) confirmed glycaemic efficacy and safety consistent with the overall programme [14].
Tirzepatide weight loss — the SURMOUNT programme
SURMOUNT-1: 72-week phase 3 double-blind RCT in 2539 adults with obesity (BMI ≥30 or ≥27 with weight-related complication) and without T2DM. Mean weight change: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. Most common adverse events: gastrointestinal, mostly mild-to-moderate, primarily during dose escalation [4].
An extended follow-up of SURMOUNT-1 (Jastreboff et al., 2025) documented sustained weight reduction and reduced progression from prediabetes to type 2 diabetes over longer observation [39].
SURMOUNT-2: in adults with obesity or overweight and T2DM, tirzepatide (10, 15 mg once weekly) over 72 weeks produced substantial body-weight reductions versus placebo [40].
SURMOUNT-5: tirzepatide -20.2% versus comparator -13.7%, head-to-head in 751 adults with obesity [5] (detail above).
SURMOUNT-J (Japan, phase 3 RCT, 225 adults without T2DM): estimated treatment differences in body weight at week 72 of -16.1% (10 mg) and -21.1% (15 mg) versus placebo; ≥5% body-weight reduction achieved by 94% (10 mg) and 96% (15 mg) versus 20% placebo [41]. The tirzepatide weight loss evidence base is among the largest for any approved obesity treatment in the phase 3 literature.
Tirzepatide results beyond glycaemia and weight
SURMOUNT-OSA: in adults with obesity and moderate-to-severe obstructive sleep apnea, tirzepatide (10 or 15 mg) over 52 weeks reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) by 25.3 events/hour (no PAP device group) and 29.3 events/hour (PAP users) versus approximately 5 events/hour with placebo [34]. This study supported the approval of tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity.
SUMMIT: in patients with heart failure with preserved ejection fraction (HFpEF — a form of heart failure where the heart's pumping fraction remains normal) and obesity, tirzepatide improved heart-failure outcomes and reduced events versus placebo [35].
SYNERGY-NASH: in adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty liver disease characterised by inflammation and fibrosis) and moderate-to-severe fibrosis, tirzepatide led to MASH resolution without worsening of fibrosis more often than placebo [36].
Cardiometabolic secondary outcomes: a SURPASS-4 substudy found favourable kidney outcomes (slower eGFR decline, reduced albuminuria) versus insulin glargine in T2DM at high cardiovascular risk [42]. An ambulatory blood-pressure substudy found tirzepatide reduced 24-hour ambulatory systolic blood pressure in adults with BMI ≥27 [43]. SURPASS-CVOT (cardiovascular outcomes trial versus dulaglutide in T2DM with atherosclerotic cardiovascular disease, 2025) provided the cardiovascular outcomes record [44].
Recent tirzepatide research 2024-2025
A 2024 pharmacovigilance analysis of FAERS post-market data characterised real-world safety signals for tirzepatide, identifying gastrointestinal events and incorrect dose administration as the most frequent categories [31]. A 2025 meta-analysis specifically examining tirzepatide gastrointestinal events across 13 trials in people with obesity without diabetes quantified the risk versus placebo and examined time-to-onset [20]. Analyses of body composition change during tirzepatide treatment have quantified the lean-mass component of weight lost and evaluated the potential role of resistance exercise [25][26]. A 2024 review of clinical consequences of delayed gastric emptying with incretin therapies addressed perioperative aspiration risk [24]. A 2024 pharmacological signalling study characterised GIP receptor variant-dependent signalling profiles for tirzepatide versus native GIP peptides, confirming biased Gas/cAMP signalling at both GIPR variants (E354 and Q354) [10]. A 2025 pharmacovigilance series on discontinuation and weight regain quantified cardiometabolic parameter worsening following weight regain after stopping tirzepatide [29].